Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) will report its financial results for the quarter ending September 30, 2021, on November 9, 2021, before the market opens. A conference call hosted by AGTC management will commence at 8:00 AM ET to discuss the financial outcomes and provide a corporate update.
AGTC specializes in gene therapies for rare retinal diseases. The company is advancing clinical trials for conditions like X-linked retinitis pigmentosa and achromatopsia, leveraging its technology platform to enhance patient outcomes.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that Sue Washer, CEO, will present at the Dry AMD Therapeutic Development Summit from October 19-21, 2021. Her presentation on October 20 at 1:45 p.m. ET will focus on the potential of AAV gene therapy in treating dry-age related macular degeneration (AMD). AGTC aims to express complement factor H as a therapeutic strategy and will highlight their optimized vector construct for dry-AMD treatment. AGTC specializes in gene therapies for rare diseases, with ongoing clinical trials in X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced the appointment of Susan Schneider as the new Chief Medical Officer and Sarah C. DiSalvatore as Vice President of Clinical Operations. Dr. Schneider, with extensive experience in ophthalmology and clinical development, joins as AGTC advances its X-Linked Retinitis Pigmentosa and Achromatopsia B3 programs into late-stage clinical trials. Ms. DiSalvatore brings strategic leadership and a strong background in gene therapy programs. Both appointments are expected to bolster AGTC's clinical capabilities and support ongoing development efforts.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced that Sue Washer, its President and CEO, will present at the 2021 Cell & Gene Meeting on the Mesa from October 12-14, 2021. The presentation is scheduled for October 13 at 11:15 AM PT, where she will discuss the advancement of late-stage clinical programs for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). AGTC focuses on gene therapies for rare inherited retinal diseases and has ongoing clinical trials and strategic partnerships aimed at addressing significant unmet medical needs.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced Sue Washer, President and CEO, will present at the 2021 Cell & Gene Management Meeting on October 13, 2021. The presentation will cover AGTC’s progress in late-stage clinical programs for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM). AGTC focuses on developing gene therapies for rare inherited retinal diseases and has key partnerships with Otonomy and Bionic Sight to advance its technology for patient needs.
AGTC to Present Clinical Trial Findings
AGTC (Nasdaq: AGTC) will present 12-month results from ongoing clinical trials for achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP) at the RD2021 symposium. Dr. Rachel Huckfeldt will present findings on September 29, highlighting the effectiveness of gene therapy for ACHM. Dr. Paul Yang will discuss XLRP therapy results, illustrating sustained improvement in visual function over 12 months. AGTC plans to advance both programs towards the next phase, aiming for FDA interaction and further trials.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology firm focused on gene therapies for inherited retinal diseases, announced that CEO Sue Washer will participate in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, at 1:20 PM ET.
Investors can access the audio webcast at http://ir.agtc.com/eventsand-presentations, with a replay available afterward on AGTC's website. The company has ongoing clinical trials for X-linked retinitis pigmentosa and achromatopsia.
Applied Genetic Technologies Corporation (Nasdaq: AGTC) reported Q4 and fiscal year 2021 results, highlighting $0.5 million in revenue for Q4, unchanged from the previous year, but down from $2.5 million in FY2020. R&D expenses rose to $10.0 million in Q4 and $44.4 million for the year, while net losses were $12.1 million and $57.8 million respectively. The company is focused on advancing clinical trials for XLRP and ACHM, with several data readouts expected in 2022. AGTC aims to initiate IND-enabling studies for preclinical programs and expand its manufacturing capabilities.
Applied Genetic Technologies Corporation (AGTC) will report its financial results for the quarter and year ended June 30, 2021, on September 23, 2021, after market close. The company's management will host a conference call at 4:30 PM ET to discuss the results and provide a corporate update. AGTC focuses on developing gene therapies for rare inherited retinal diseases and is currently conducting clinical trials in X-linked retinitis pigmentosa and achromatopsia. The company is also advancing multiple preclinical programs and has strategic partnerships to enhance its pipeline.
Applied Genetic Technologies Corporation (AGTC) announced that Jill Dolgin and Halley Losekamp will speak at the Clinical Trials in Rare Diseases Conference on September 14, 2021. Dolgin will discuss effective collaboration with patients and advocacy groups, while Losekamp will present a case study on patient recruitment in rare diseases. AGTC emphasizes the importance of inclusive and accessible studies, particularly during the COVID-19 pandemic. The company is focused on developing gene therapies for inherited retinal diseases, currently conducting trials for X-linked retinitis pigmentosa and achromatopsia.